Long-acting injectable antipsychotics in the first-episode schizophrenia: a clinical perspective (analytical review)
Suggested citation:
Lyubov EB. [Long-acting injectable antipsychotics in the first-episode schizophrenia: a clinical perspective (analytical review)]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2013;(6):59-69. Russian
If there is a paucity of evidence-based data, many experts recommend prescribing long-acting injectable antipsychotics (LAIs) (mostly risperdal consta (risperidone) and/or paliperidone palmitate, i.e. second-generation atypical antipsychotics) in the early stages of schizophrenia. Early use of depot antipsychotics AA can significantly reduce the risk of relapse (rehospitalization) while promoting social and labour reintegration of patients and improving their quality of life. Depot antipsychotics tend to improve treatment outcomes due to compliance especially in patients who have benefited from oral administration of these medications in the past and agreed to receive LAIs. Combined benefits of AA medications with guaranteed provision of treatment offer the possibility of recommending their use in the management of first-episode psychosis. However, the potential of depo antipsychotics has so far been largely underutilized in clinical practice. Psychiatrists should reconsider their negative attitude towards long-acting or depot antipsychotics; what is important is that they are made available to a wider segment of the population.
1. Будза В.Г., Отмахов А.П., Прусс Г.Б. Отделение первого психотического эпизода - новая форма организации психиатрической помощи больным шизофренией // Соц. и клин. психиатрия. - 2005. - Т. 15, вып. 4. - С. 58-66. 2. Былим И.А., Любов Е.Б. Первый эпизод шизофрении: клинико-социальный и экономический эффекты целевой психосоциальной помощи // Психическое здоровье. - 2011. - № 1(56). - С. 60-65 3. Гурович И.Я., Любов Е.Б. Фармакоэпидемиология и фармакоэкономика в психиатрии. - М.: Медпрактика-М, 2003. - 264 с. 4. Киселев Л.С., Сочнева З.Г. Закономерности начала, течения и исходов основных психических заболеваний. - Рига: Зинатне, 1988. - 236 с. 5. Любов Е.Б. Проблема несоблюдения лекарственного режима в психиатрической практике // Соц. и клин. психиатрия. - 2001. - Т. 11, вып. 1. - С. 89-101. 6. Любов Е.Б. Рациональный выбор пролонгированной формы рисполепта конста: клиническое и фармакоэкономическое обоснование // Психиатрия и психофармакотер. - 2008. - Т. 10, Т 2. - С. 43-49. 7. Любов Е.Б. Палиперидон пальмитат - новая возможность фармакотерапии шизофрении // Соц. и клин. психиатрия. - 2011. - Т. 11, вып. 2. - С. 43-50. 8. Любов Е.Б., Бессонова А.А. Первый эпизод шизофрении: клинико-эпидемиологический и социально-экономический аспекты // Рос. психиатр. журн. - 2008. - № 2. - С. 46-50. 9. Любов Е.Б., Бугрова Е.И. Несоблюдение режима внебольничной психофармакотерапии больными шизофренией: клинико-социальные и экономические аспекты // Рос. психиатр. журн. - 2007. - № 5. - С. 65-70. 10. Первый психотический эпизод (проблемы и психиатрическая помощь) / Под ред. И.Я. Гуровича, А.Б. Шмуклера. - М.: МЕДПРАКТИКА-М, 2010. - 544 с. 11. Психиатрическая помощь больным шизофренией: клиническое руководство / Под ред. В.Н. Краснова и др. - 2-е изд. - М.: Медпрактика-М, 2007. - 260 с. 12. Addington J. Draft consеnsus statement-principles and practice in early psychosis // Implementing Early Intervention in Psychosis: a Guide to Establishing Early Psychosis Services / Eds J. Edwards, P. McGorry. - London: Martin Dunitz, 2002. - P. 145-155. 13. Adams C.E., Fenton M.K.P., Quraishi S., David A.S. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia // Br. J. Psychiatry. - 2001. - Vol. 179. - P. 290-299. 14. Aggarwal G., Dhawan S., Harikumar S.L. Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine // Pharm. Develop. Technol. - 2011. - Vol. 2011, N 108374. 15. Aggarwal G., Dhawan S., Harikumar S.L. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone // Drug Develop. Industr. Pharm. - 2012. - Vol. 2012, N 036390. 16. Аlvarez-Jimеnez M., Parker A.G., Hetrick S.E. et al. Preventing the Second Episode: A Systematic Review and Meta-Analysis of Psychosocial and Pharmacological Trials in First-Episode Psychosis // Schizophr. Bull. - 2011. - Vol. 37. - P. 619-630. 17. Amann L.C., Gandal M.J., Lin R. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia // Pharm. Res. - 2010. - Vol. 27. - Р. 1730-1737. 18. Andreasen N.C., Carpenter W.T., Kane J.M. et al. Remission in schizophrenia: proposed criteria and rationale for consensus // Am. J. Psychiatry. - 2005. - Vol. 162. - P. 441-449. 19. Archie S., Hamilton Wiison J., Woodwardet K. et al. Psychotic Disorders Clinic and First-Episode Psychosis: A Program Evaluation // Can. J. Psychiatry. - 2005. - Vоl. 50. - Р. 46-51. 20. Argo T.R., Crimson M.L., Miller A.L. et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia. - The Texas Department of State Health Services, 2007. 21. Ascher-Svanum H., Peng X., Faries D. et al. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients // BMC Psychiatry. - 2009. - Vol. 9. - P. 46. 22. Association CP. Clinical practice guidelines. Treatment of schizophrenia // Can. J. Psychiatry. - 2005. - Vоl. 50, suppl. 1. - Р. 7S-57S. 23. Barnes T.R., Shingleton-Smith A., Paton C. Antipsychotic longacting injections: prescribing practice in the UK // Br. J. Psychiatry. - 2009. Suppl. - Vol. 52. - S. 37-42. 24. Barnes T.R. Schizophrenia Consensus Group of British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology // J. Psychopharmacol. - 2011. - Vol. 25. - P. 567-620. 25. Barrio P., Batalla A., Castellvн P. et al. Effectiveness of longacting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study // Int. Clin. Psychopharmacol. - 2013. - Vol. 28, N 4. - P. 164-170. 26. Bartzokis G., Lu P.H., Amar C.P. et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory // Schizophr. Res. - 2011. - Vol. 132, N 1. - P. 35-41. 27. Birchwood M., Todd P., Jackson C. Early intervention in psychosis. The critical period hypothesis // Br. J. Psychiatry. - 1998. - Vol. 172, suppl. 33. - P. 53-59. 28. Buchanan R.W., Kreyenbuhl J., Kelly D.L. et al. Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements // Schizophr. Bull. - 2010. - Vol. 36. - P. 71-93. 29. Chue P., Chue J. A review of paliperidone palmitate // Expert Rev. Neurother. - 2012. - Vol. 12. - P. 1383-1397. 30. Chue P., Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics // CNS Drugs. - 2007. - Vol. 21. - P. 441-448. 31. Coldham E.L., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis // Acta Psychiatr. Scand. - 2002. - Vol. 106. - P. 286-290. 32. Crossley N.A., McGuire P., Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: metaanalysis // Br. J. Psychiatry. - 2010. - Vol. 196. - P. 434-439. 33. Cullberg J., Mattsson M., Levander S. et al. Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish "Parachute Project" and two comparison groups // Acta Psychiatr. Scand. - 2006. - Vоl. 114. - Р. 274-281. 34. Csernansky J.G., Schuchart E.K. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics // CNS Drugs. - 2002. - Vol. 16. - Р. 473-484. 35. Davis J.M., Chen N. Choice of maintenance medication for schizophrenia // J. Clin. Psychiatry. - 2003. - Vol. 64, suppl. 16. - P. 24-33. 36. Davis J.M., Metalon L., Watanabe M.D., Blake L. Depot antipsychotic drugs. Place in therapy // Drugs. - 1994. - Vol. 47. - P. 741-773. 37. Drake R.J., Haley C.J., Akhtar S., Lewis S.W. Causes and consequences of duration of untreated psychosis in schizophrenia // Br. J. Psychiatry. - 2000. - Vol. 177. - P. 511-515. 38. Eaton W.W., Thara R., Federman E., Tien A. Remission and relapse in schizophrenia: the Madras Longitudinal Study // J. Nerv. Ment. Dis. - 1998. - Vol. 186. - Р. 357-363. 39. Emsley R., Chiliza B., Asmal L., Harvey B.H. The nature of relapse in schizophrenia // BMC Psychiatry. - 2013. - Vol. 13. - P. 50. 40. Emsley R., Oosthuizen P., Koen L. et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies // Clin. Ther. - 2008. - Vol. 30. - P. 2378-2386. 41. Fleischhacker W.W. Second-generation antipsychotic long-acting injections: systematic review // Br. J. Psychiatry. - 2009. Suppl. - Vol. 52. - S29-S36. 42. Fraser R., Berger G., Killackey E., McGorry P. Emerging psychosis in young people - part 3 - key issues for prolonged recovery // Aust. Fam. Physician. - 2006. - Vol. 35. - P. 329-333. 43. Gaebel W., Riesbeck M., Wцlwer W. et al. Rates and predictors of remission in first-episode schizophrenia within 1year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia // Schizophr. Res. - 2013 S0920-9964(13)002120. doi: 10.1016/j.schres.2013.04.012. [Epub ahead of print] 44. Gass P., Mas S., Molina O. et al. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2012. - Vol. 36. - Р. 71-77. 45. Geerts P., Martinez G., Schreiner A. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses // BMC Psychiatry. - 2013. - Vol. 13. - P. 58. 46. Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients // Arch. Gen. Psychiatry. - 1995. - Vol. 52. - P. 173-188. 47. Gitlin M., Nuechterlein K., Subotnik K.L. et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia // Am. J. Psychiatry. - 2001. - Vol. 158. - P. 1835-1842. 48. Glazer W.M., Kane J.M. Depot neuroleptic therapy: an underutilized treatment option // J. Clin. Psychiatry. - 1992. - Vol. 53. - P. 426-433. 49. Haddad P.M., Taylor M., Niaz O.S. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies // Br. J. Psychiatry. - 2009. - Vol. 195, suppl. 52. - P. s20-s28. 50. Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Pt 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects // World J. Biol. Psychiatry. - 2013. - Vol. 14. - P. 2-44. 51. Heres S., Reichhart T., Hamann J. et al. Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia // Eur. Psychiatry. - 2011. - Vol. 26. - P. 297-301. 52. Hough D., Lindenmayer J.P., Gopal S. et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2009. - Vol. 33. - P. 1022-1031. 53. Jaeger M., Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists // Psychiatry Res. - 2010. - Vol. 175, N 1-2. - P. 58-62. 54. Jeong H-G., Lee M.-S. Long-acting Injectable Antipsychotics in First-episode Schizophrenia // Clin. Psychopharmacol. Neurosci. - 2013. - Vol. 11. - P. 1-6. 55. Kahn R.S., Fleischhacker W.W., Boter H. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial // Lancet. - 2008. - Vol. 371, N 9618. - P. 1085-1097. 56. Kane J.M. Treatment adherence and long-term outcomes // CNS Spectr. - 2007. - Vol. 12, suppl. 17. - P. 21-26. 57. Kane J.M., Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections // Br. J. Psychiatry. - 2009. - Vol. 195, suppl. - P. S63-S67. 58. Kim B., Lee S.H., Choi T.K. et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2008. - Vol. 32. - P. 1231-1235. 59. iComparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients // Int. Clin. Psychopharmacol. - 2013. - Vol. 28. - P. 80-86. 60. Kim S., Solari H., Weiden P.J., Bishop J.R. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults // Patient Prefer Adherence. - 2012. - Vol. 6. - P. 533-545. 61. Kishimoto T., Robenzadeh A., Leucht C. et al. Long-Acting Injectable vs. Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials // Schizophr. Bull. - 2012. doi: 10.1093/schbul/sbs150 62. Kreyenbuhl J., Slade E.P., Medoff D.R. et al. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia // Schizophr. Res. - 2011. - Vol. 131, N 1-3. - P. 127-132. 63. Lacro J.P., Dunn L.B., Dolder C.R. et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature // J. Clin. Psychiatry. - 2002. - Vol. 63. - P. 892-909. 64. Lambert M., Conus P., Lambert T., McGorry P.D. Pharmacotherapy of first-episode psychosis // Expert Opin. Pharmacother. - 2003. - Vol. 4. - P. 17-50. 65. Lee S.H., Choi T.K., Suh S. et al. Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection // Psychiatr. Res. - 2010. - Vol. 175, N 3. - P. 195-199. 66. Lehman A.F., Lieberman J.A., Dixon L.B. et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. // Am. J. Psychiatry. - 2004. - Vol. 161, suppl. 2. - P. 1-56. 67. Leucht C., Heres S., Kane J.M. et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials // Schizophr. Res. - 2011. - Vol. 127, N 1-3. - P. 83-92. 68. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia // J. Clin. Psychiatry. - 2006. - Vol. 67, suppl. 5. - P. 3-8. 69. Leucht S., Tardy M., Komossa K. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis // Lancet. - 2012. - Vol. 379. - P. 2063-2071. 70. Lieberman J.A., Bymaster F.P., Meltzer H.Y. et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection // Pharmacol. Rev. - 2008. - Vol. 60. - P. 358-403. 71. Lieberman J.A., Perkins D., Belger A. et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches // Biol. Psychiatry. - 2001. - Vol. 50. - P. 884-897. 72. iPartial compliance in schizophrenia and the impact on patient outcomes // Psychiatr. Res. - 2008. - Vol. 161. - P. 235-247. 73. Love R.C. Strategies for increasing treatment compliance: the role of long- acting antipsychotics // Am. J. Health Syst. Pharm. - 2002. - Vol. 59, suppl. 8. - P. S10-S15. 74. Malla A., Binder C., Chue P. Comparison of long-acting injectable risperidone and oral novel antipsychotic drugs for treatment in early phase of schizophrenia spectrum psychosis // Proceedings of the 61st Annual Convention Society Biol. Psychiatry. - Toronto, 2006. 75. McEvoy J.P., Lieberman J.A., Perkins D.O. et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison // Am. J. Psychiatry. - 2007. - Vol. 164. - P. 1050-1060. 76. Mentschel C. Depot-drugs may reduce relapse rates in schizophrenic outpatients: a meta-analysis // Proceedings of the 156 th meeting of the American Psychiatric Association. - San Francisco, 2003. - P. 71. 77. Miller B.J. A review of second-generation antipsychotic discontinuation in first-episode psychosis // J. Psychiatr. Pract. - 2008. - Vol. 14. - P. 289-300. 78. Mojtabai R., Lavelle J., Gibson P.J. et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996 // Psychiatr. Serv. - 2002. - Vol. 53. - P. 337-339. 79. Naber D. Olanzapine pamoate for the treatment of schizophrenia // Expert Opin. Pharmacother. - 2011. - Vol. 12. - P. 627-633. 80. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era // Acta Psychiatr. Scand. - 2007. - Vol. 115, N 4. - P. 260-267. 81. National Institute for Health and Clinical Excellence (NICE) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82). NICE. - London, 2009 (http://www.nice.org.uk/CG82). 82. Nussbaum A.M., Stroup T.S. Paliperidone palmitate for schizophrenia // Cochrane Database Syst. Rev. - 2012: CD008296. 83. Olivares J.M., Alptekin K., Azorin J.-M. et al. Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa // Patient Prefer Adherence. - 2013. - Vol. 7. - P. 121-132. 84. Parellada E., Velligan D.I., Emsley R. et al. Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia // Schizophr. Res. Treat. - 2012. - Vol. 2012, N 318535. - 3 p. 85. Patel M.X., Haddad P.M., Chaudhry I.B. et al. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years // J. Psychopharmacol. - 2010. - Vol. 24. - P. 1473-1482. 86. Pereira S., Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication // Acta Psychiatr. Scand. - 1997. - Vol. 95. - Р. 464-468. 87. Perkins D.O., Gu H., Weiden P.J. et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder: A randomized doubleblind, flexible-dose, multicenter study // J. Clin. Psychiatry. - 2008. - Vol. 69. - Р. 106-113. 88. Proctor S.E., Mitford E., Paxton R. First episode psychosis: a novel methodology reveals higher than expected incidence; a reality-based population profile in Northumberland, UK // J. Evaluat. Clin. Pract. - 2004. - Vol. 10. - Р. 539-547. 89. Robinson D., Woerner M.G., Alvir J.M. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder // Arch. Gen. Psychiatry. - 1999. - Vol. 56. - P. 241-247. 90. Rooney K., Jones P., Sawh S. et al. Paliperidone palmitate efficacy and safety in the treatment of schizophrenia: a systematic review and meta-analysis // http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013004713 91. Rosenheck R.A., Krystal J.H., Lew R. et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia // N. Engl. J. Med. - 2011. - Vol. 364. - Р. 842-851. 92. Samalin L., Charpeaud T., Blanc O. et al. Clinicians’ attitudes toward the use of long-acting injectable antipsychotics // J. Nerv. Ment. Dis. - 2013. - Vol. 201. - P. 553-559. 93. Schooler N.R. Relapse and rehospitalization: comparing oral and depot antipsychotics // J. Clin. Psychiatry. - 2003. - Vol. 64, suppl. 16. - P. 14-17. 94. Sun D., Stuart G.W., Jenkinson M. et al. Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study // Mol. Psychiatry. - 2009. - Vol. 14. - P. 976-986. 95. Svedberg B., Backenroth-Ohsako G., Lьtzйn K. On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication // Int. J. Ment. Health Nurs. - 2003. - Vol. 12, N 2. - P. 110-118. 96. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, “just the facts”: 4. Clinical features and conceptualization // Schizophr. Res. - 2009. - Vol. 110, N 1-3. - Р. 1-23. 97. Tiihonen J., Haukka J., Taylor M. et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia // Am. J. Psychiatry. - 2011. - Vol. 168. - P. 603-609. 98. Tourian L., Margolese H.C. Extended-release intramuscular aripiprazole for maintenance pharmacotherapy in schizophrenia and related disorders // Neuropsychiatry. - 2013. - Vol. 3, N 3. - P. 345-354. 99. Uсok A., Polat A., Сakir S. et al. One year outcome in first episode schizophrenia: Predictors of relapse // Eur. Arch. Psychiatry Clin. Neurosci. - 2006. - Vol. 256. - P. 37-43. 100. Valenstein M., Ganoczy D., McCarthy J.F. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review // J. Clin. Psychiatry. - 2006. - Vol. 67. - P. 1542-1550. 101. Velligan D.I., Weiden P.J., Sajatovic M. et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness // J. Clin. Psychiatry. - 2009. - Vol. 70, suppl. 4. - P. 1-46. 102. Verdoux H., Lengronne J., Liraud F. et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects // Acta Psychiatr. Scand. - 2000. - Vol. 102. - Р. 203 -210. 103. Viala A., Cornic F., Vacheron M.-N. Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia // Schizophr. Res. Treat. - 2012. - Vol. 2012, N 368687. - 5 p. 104. Waddell L., Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review // Br. J. Psychiatry. - 2009. Suppl. - Vol. 195. - P. S43-50. 105. Walburn J., Gray R., Gournay K. et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication // Br. J. Psychiatry. - 2001. - Vol. 179. - P. 300-307. 106. Weiden P.J., Kozma C., Grogg A., Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia // Psychiatr. Serv. - 2004. - Vol. 55. - Р. 886-891. 107. Weiden P.J., Schooler N.R., Weedon J.C. et al. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study // J. Clin. Psychiatry. - 2012. - Vol. 73. - P. 1224-1233. 108. Wiersma D., Nienhuis F.J., Slooff C.J. et al. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort // Schizophr. Bull. - 1998. - Vol. 24. - Р. 75-85. 109. Yamada K., Watanabe K., Nemoto N. et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study // Psychiatry Res. - 2006. - Vol. 141. - P. 61-69. 110. Zhornitsky S., Stip E. Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review // Schizophr. Res. Treat. - Vol. 2012, N 407171. - 12 p.
DOI: http://dx.doi.org/10.24411/1560-957X-2013-11377
Article Metrics
Metrics powered by PLOS ALM